Top

Published in:

01-03-2014 | Breast

¹⁸F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes

Authors: Hye Ryoung Koo, Jeong Seon Park, Keon Wook Kang, Nariya Cho, Jung Min Chang, Min Sun Bae, Won Hwa Kim, Su Hyun Lee, Mi Young Kim, Jin You Kim, Mirinae Seo, Woo Kyung Moon

Published in: European Radiology | Issue 3/2014

Abstract

Objectives

To determine whether a correlation exists between maximum standardized uptake value (SUV_max) on ¹⁸F-fluorodeoxyglucose positron emission tomography (FDG-PET) and the subtypes of breast cancer.

Methods

This retrospective study involved 548 patients (mean age 51.6 years, range 21–81 years) with 552 index breast cancers (mean size 2.57 cm, range 1.0–14.5 cm). The correlation between ¹⁸F-FDG uptake in PET/CT, expressed as SUV_max, and immunohistochemically defined subtypes (luminal A, luminal B, human epidermal growth factor receptor 2 (HER2) positive and triple negative) was analyzed.

Results

The mean SUV_max value of the 552 tumours was 6.07 ± 4.63 (range 0.9–32.8). The subtypes of the 552 tumours were 334 (60 %) luminal A, 66 (12 %) luminal B, 60 (11 %) HER2 positive and 92 (17 %) triple negative, for which the mean SUV_max values were 4.69 ± 3.45, 6.51 ± 4.18, 7.44 ± 4.73 and 9.83 ± 6.03, respectively. In a multivariate regression analysis, triple-negative and HER2-positive tumours had 1.67-fold (P < 0.001) and 1.27-fold (P = 0.009) higher SUV_max values, respectively, than luminal A tumours after adjustment for invasive tumour size, lymph node involvement status and histologic grade.

Conclusion

FDG uptake was independently associated with subtypes of invasive breast cancer. Triple-negative and HER2-positive breast cancers showed higher SUV_max values than luminal A tumours.

Key Points

• ¹⁸ F-FDG PET demonstrates increased tissue glucose metabolism, a hallmark of cancers.

• Immunohistochemically defined subtypes appear significantly associated with FDG uptake (expressed as SUV _max ).

• Triple-negative tumours had 1.67-fold higher SUV _max values than luminal A tumours.

• HER2-positive tumours had 1.27-fold higher SUV _max values than luminal A tumours.

Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef

van ’t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536CrossRef

van’t Veer LJ, Paik S, Hayes DF (2005) Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol 23:1631–1635CrossRef

Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826PubMedCrossRef

Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874PubMedCentralPubMedCrossRef

Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750PubMedCrossRef

Hugh J, Hanson J, Cheang MC et al (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27:1168–1176PubMedCrossRef

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736–1747PubMedCrossRef

Dubsky P, Filipits M, Jakesz R et al (2013) EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol 24:640–647PubMedCrossRef

10.

Niemiec J, Adamczyk A, Malecki K, Ambicka A, Rys J (2013) Tumor grade and matrix metalloproteinase 2 expression in stromal fibroblasts help to stratify the high-risk group of patients with early breast cancer identified on the basis of St Gallen recommendations. Clin Breast Cancer 13:119–128PubMedCrossRef

11.

Koolen BB, Vrancken Peeters MJ, Aukema TS et al (2012) 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat 131:117–126PubMedCrossRef

12.

Aukema TS, Rutgers EJ, Vogel WV et al (2010) The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. Eur J Surg Oncol 36:387–392PubMedCrossRef

13.

Hatt M, Groheux D, Martineau A et al (2013) Comparison Between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. J Nucl Med 54:341–349PubMedCrossRef

14.

Groheux D, Hindie E, Delord M et al (2012) Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst 104:1879–1887PubMedCrossRef

15.

Song BI, Lee SW, Jeong SY et al (2012) 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer. J Nucl Med 53:1337–1344PubMedCrossRef

16.

Ueda S, Kondoh N, Tsuda H et al (2008) Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer. BMC Cancer 8:384PubMedCentralPubMedCrossRef

17.

Specht JM, Kurland BF, Montgomery SK et al (2010) Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res 16:2803–2810PubMedCentralPubMedCrossRef

18.

Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef

19.

Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795PubMedCrossRef

20.

Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133–1144PubMedCrossRef

21.

Jadvar H, Alavi A, Gambhir SS (2009) 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med 50:1820–1827PubMedCentralPubMedCrossRef

22.

Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474PubMedCrossRef

23.

Groheux D, Giacchetti S, Moretti JL et al (2011) Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 38:426–435PubMedCrossRef

24.

Avril N, Menzel M, Dose J et al (2001) Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 42:9–16PubMed

25.

Buck A, Schirrmeister H, Kuhn T et al (2002) FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 29:1317–1323PubMedCrossRef

26.

Kennecke H, Yerushalmi R, Woods R et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271–3277PubMedCrossRef

27.

Gianni L, Dafni U, Gelber RD et al (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236–244PubMedCrossRef

28.

Caudle AS, Yu TK, Tucker SL et al (2012) Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res 14:R83PubMedCentralPubMedCrossRef

29.

Basu S, Chen W, Tchou J et al (2008) Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 112:995–1000PubMedCrossRef

30.

Palaskas N, Larson SM, Schultz N et al (2011) 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res 71:5164–5174PubMedCentralPubMedCrossRef

31.

Ueda S, Tsuda H, Asakawa H et al (2008) Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol 38:250–258PubMedCrossRef

32.

Koolen BB, Vrancken Peeters MJ, Wesseling J et al (2012) Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 39:1830–1838PubMedCrossRef

33.

Koolen BB, Pengel KE, Wesseling J et al (2013) FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. Breast. doi:10.1016/j.breast.2012.12.020 PubMed

34.

Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A (2006) Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 98:267–274PubMedCrossRef

Title: 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes
Authors: Hye Ryoung Koo
Jeong Seon Park
Keon Wook Kang
Nariya Cho
Jung Min Chang
Min Sun Bae
Won Hwa Kim
Su Hyun Lee
Mi Young Kim
Jin You Kim
Mirinae Seo
Woo Kyung Moon
Publication date: 01-03-2014
Publisher: Springer Berlin Heidelberg
Published in: European Radiology / Issue 3/2014
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-013-3037-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

¹⁸F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes

Abstract

Objectives

Methods

Results

Conclusion

Key Points

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusion

Key Points

Please log in to get access to this content

Other articles of this Issue 3/2014

Evaluation of conventional, dynamic contrast enhanced and diffusion weighted MRI for quantitative Crohn’s disease assessment with histopathology of surgical specimens

Thoracic outlet syndrome in 3T MR neurography—fibrous bands causing discernible lesions of the lower brachial plexus

Radiological work-up after mass casualty incidents: are ATLS guidelines applicable?

Painful paediatric hip: frog-leg lateral view only!

Urinary stone detection and characterisation with dual-energy CT urography after furosemide intravenous injection: preliminary results

320-row CT coronary angiography predicts freedom from revascularisation and acts as a gatekeeper to defer invasive angiography in stable coronary artery disease: a fractional flow reserve-correlated study